Webinars.
Educational insights about GARD
When you watch our webinars, you will learn in what ways GARD can support your testing needs. We cover essential topics that range from genomics and machine learning and why GARD has such robust prediction for in vitro sensitization testing, to difficult-to-test samples and quantitative potency assessment.
© SenzaGen
Interested in more information?
Contact us to discuss how the GARD assays can support your testing needs.
May 27, 2021
Skin Sensitizing Potency Assessment: Filling in data gaps
By Dr Andy Forreryd and Dr Tim Lindberg
April 28, 2021
In vitro technology replacing animal models for skin sensitization testing
By Anna Chérouvrier Hansson and Ulrika T Mattson
April 14, 2021
SenzaGen’s 2021 SOT poster presentations
By Dr Henrik Johansson and Dr Ron Brown
- Poster #1. Quantitative Sensitizing Potency Assessment Using GARD™skin Dose-Response | Download a copy
- Poster #2. Applicability Domain of the GARD™skin Medical Device Test for In Vitro Skin Sensitization Testing of Medical Devices 🏅 (MDCPSS Best Overall Abstract) | Download a copy
March 11, 2021
Joint webinar in French: Cosmetic Safety 3.0 – Webinaire France (new session)
By PKDerm, GenEvolutioN, CEHTRA and SenzaGen
February 25, 2021
How is GARD™ used for sensitization testing?
By Rose-Marie Jenvert, PhD, SenzaGen
January 27, 2021
Why choose GARD™ for sensitization testing?
By Andy Forreryd, PhD, SenzaGen
October 21, 2020
Safer Medical Devices – in vitro skin sensitization testing with human relevance and high accuracy
By Rose-Marie Jenvert, PhD, and Joshua Schmidt, PhD, SenzaGen
October 6, 2020
Joint webinar in French: Cosmetic Safety 3.0 – Webinaire France
By PKDerm, GenEvolutioN, SenzaGen
September 15, 2020
Joint webinar: Your Guide to GARD®
– New generation skin sensitisation testing technologies explained
By Carol Treasure, PhD, XCellR8 and Andy Forreryd, PhD, SenzaGen AB
June 17, 2020
Web-based launch: The NEW GARDskin Dose-Response
By Andy Forreryd, PhD, SenzaGen AB
May 26, 2020
Genomics and Machine Learning for In Vitro Sensitization Testing of Challenging Chemicals
By Henrik Johansson, PhD, and Andy Forreryd, PhD, SenzaGen AB
March 26, 2020
Web-based conference on “Difficult-to-test” substances and regulatory testing
By Andy Forreryd, SenzaGen AB and guest speakers from Eurofins, Lubrizol and MB Research Labs
Session recordings
Dr Andy Forreryd, SenzaGen
Helge Gehrke, Eurofins BioPharma Product Testing
Dr. George DeGeorge, MB Research Labs
February, 2020
In vitro sensitization testing based on genomics and machine learning
By Angelica Johansson, SenzaGen AB
October, 2019
In vitro sensitization testing of Medical Devices – GARDskin Medical Device
By Rose-Marie Jenvert, PhD, SenzaGen
September 2019
How are the in vitro GARD™ assays used in real life? – Cases and applications for testing of skin and respiratory sensitizers
By Andy Forreryd, PhD, SenzaGen
April 2019
Genomics and Machine Learning – All you need to know about the GARD™ technology for in vitro sensitization testing
By Andy Forreryd, PhD, SenzaGen
